Tracking epitope-specific antiviral CD4+ T cell responses to a live attenuated vaccine reveals ongoing functional responses

Vaccine

Volumn 27, Issue 52, 2009, Pages 7398-7401

  Jones, L ^a,b   Malavige, G ^a   Jeffery, K ^c   Kemp, E ^c   Breuer, J ^e   Klenerman, P ^b,c,d   Ogg, G S ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Tetramer; Vaccinees; Varicella

Indexed keywords

EPITOPE; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TETRAMER; VARICELLA ZOSTER VACCINE;

ADULT; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; DRUG RESPONSE; FEMALE; HERPES ZOSTER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CHICKENPOX; CHICKENPOX VACCINE; EPITOPES, T-LYMPHOCYTE; FEMALE; HEALTH PERSONNEL; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 70849095201     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.081     Document Type: Article

References (17)

1. Arvin A.M. Varicella-zoster virus: molecular virology and virus-host interactions. Curr Opin Microbiol 4 4 (2001) 442-449
2. Arvin A.M., Kinney-Thomas E., Shriver K., Grose C., Koropchak C.M., Scranton E., et al. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol 137 4 (1986) 1346-1351
3. Diaz P.S., Smith S., Hunter E., and Arvin A.M. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 142 January (2) (1989) 636-641
4. Levin M.J., Murray M., Rotbart H.A., Zerbe G.O., White C.J., and Hayward A.R. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 166 2 (1992) 253-259
5. Levin M.J., Murray M., Zerbe G.O., White C.J., and Hayward A.R. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 170 3 (1994) 522-526
6. Zerboni L., Nader S., Aoki K., and Arvin A.M. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 177 6 (1998) 1701-1704
7. Jenkins D.E., Yasukawa L.L., Bergen R., Benike C., Engleman E.G., and Arvin A.M. Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. J Immunol 162 January (1) (1999) 560-567
8. Frey C.R., Sharp M.A., Min A.S., Schmid D.S., Loparev V., and Arvin A.M. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 188 July (1) (2003) 40-52
9. Bunce M., O'Neill C.M., Barnardo M.C., Krausa P., Browning M.J., Morris P.J., et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46 5 (1995) 355-367
10. Jones L., Black A.P., Malavige G.N., and Ogg G.S. Phenotypic analysis of human CD4(+) T cells specific for immediate early 63 protein of varicella-zoster virus. Eur J Immunol 37 12 (2007) 3393-3403
11. Malavige G.N., Jones L., Kamaladasa S.D., Wijewickrama A., Seneviratne S.L., Black A.P., et al. Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS ONE 3 11 (2008) e3789
12. Maple P.A., Gray J., Breuer J., Kafatos G., Parker S., and Brown D. Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clin Vaccine Immunol 13 2 (2006) 214-218
13. + T cells after primary infection. J Virol 80 19 (2006) 9772-9778
14. + T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 152 3 (2008) 522-531
15. + T cells many decades after primary infection. J Infect Dis 195 March (5) (2007) 660-664
16. + T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur J Immunol 37 12 (2007) 3393-3403
17. Tan L.C., Gudgeon N., Annels N.E., Hansasuta P., O'Callaghan C.A., Rowland-Jones S., et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 162 February (3) (1999) 1827-1835